Assignee
CYCLACEL LTD
GB·44 granted patents·40 pending applications·687 citations·filing 1995–2021
Top patents by PatentIndex Score
84 records- 0195US6972198B2Methods and compositions using protein binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 6, 2005·89 cites·12 claims
- 0292US6531479B2Anti-cancer compoundsCYCLACEL LTD·Filed 2001·Granted Mar 11, 2003·52 cites·23 claims
- 0391US7060506B2Compositions and methods for monitoring the modification of modification dependent binding partner polypeptidesCYCLACEL LTD·Filed 2001·Granted Jun 13, 2006·112 cites·18 claims
- 0491US6699854B2Anti-cancer compoundsCYCLACEL LTD·Filed 2002·Granted Mar 2, 2004·40 cites·26 claims
- 0588US7897605B2Pyrimidine compoundsCYCLACEL LTD·Filed 2008·Granted Mar 1, 2011·14 cites·6 claims
- 0687US8975239B2Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaineCYCLACEL LTD·Filed 2013·Granted Mar 10, 2015·16 cites·15 claims
- 0786US7101967B2Transport vectorsCYCLACEL LTD·Filed 2001·Granted Sep 5, 2006·13 cites·28 claims
- 0886US6670144B1Compositions and methods for monitoring the phosphorylation of natural binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 30, 2003·26 cites·6 claims
- 0984US8349792B2Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agentCYCLACEL LTD·Filed 2007·Granted Jan 8, 2013·3 cites·14 claims
- 1083US6808874B2Methods of monitoring enzyme activityCYCLACEL LTD·Filed 2001·Granted Oct 26, 2004·22 cites·60 claims
- 1182US6472507B1Carrier based drug delivery systemCYCLACEL LTD·Filed 1999·Granted Oct 29, 2002·57 cites·40 claims
- 1281US7582642B2Purine derivativesCYCLACEL LTD·Filed 2005·Granted Sep 1, 2009·5 cites·10 claims
- 1381US7427627B2N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compoundsCYCLACEL LTD·Filed 2006·Granted Sep 23, 2008·6 cites·25 claims
- 1480US7576091B2Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinasesCYCLACEL LTD·Filed 2006·Granted Aug 18, 2009·7 cites·17 claims
- 1580US7544689B2Purine derivativesCYCLACEL LTD·Filed 2005·Granted Jun 9, 2009·4 cites·10 claims
- 1680US7262202B2Inhibitors of cyclin dependent kinases as anti-cancer agentCYCLACEL LTD·Filed 2003·Granted Aug 28, 2007·13 cites·41 claims
- 1780US6828106B2Methods and compositions using coiled binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 7, 2004·11 cites·8 claims
- 1879US6992169B2Carrier based drug delivery systemCYCLACEL LTD·Filed 2002·Granted Jan 31, 2006·9 cites·40 claims
- 1978US7902361B2Pyrimidin-4-yl-3, 4-thione compounds and their use in therapyCYCLACEL LTD·Filed 2006·Granted Mar 8, 2011·7 cites·28 claims
- 2078US7388015B2N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compoundsCYCLACEL LTD·Filed 2004·Granted Jun 17, 2008·13 cites·25 claims
- 2176US7449544B2p21 peptidesCYCLACEL LTD·Filed 2003·Granted Nov 11, 2008·11 cites·9 claims
- 2275US7105307B2Compositions and methods for screening for modulators of enzymatic activityCYCLACEL LTD·Filed 2002·Granted Sep 12, 2006·5 cites·34 claims
- 2374US9675631B2Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabineCYCLACEL LTD·Filed 2013·Granted Jun 13, 2017·2 cites·20 claims
- 2472US6852906B2Assay for measuring enzyme activity in vivoCYCLACEL LTD·Filed 2002·Granted Feb 8, 2005·13 cites·19 claims
- 2569US9573951B2Crystalline forms of a purine derivativeCYCLACEL LTD·Filed 2014·Granted Feb 21, 2017·1 cites·5 claims
- 2669US7772207B2Combination of a CDK inhibitor and CS-682 or a metabolite thereofCYCLACEL LTD·Filed 2004·Granted Aug 10, 2010·9 cites·5 claims
- 2768US9133199B2Pyrimidine derivatives as protein kinase inhibitorsCYCLACEL LTD·Filed 2013·Granted Sep 15, 2015·1 cites·14 claims
- 2868US7153931B1Transport vectorsCYCLACEL LTD·Filed 1999·Granted Dec 26, 2006·15 cites·93 claims
- 2965US7612079B22,6,9-substituted purine derivatives and their use in the treatment of proliferative disordersCYCLACEL LTD·Filed 2003·Granted Nov 3, 2009·4 cites·22 claims
- 3065US6465199B1Compositions and methods for monitoring the modification of natural binding partnersCYCLACEL LTD·Filed 1999·Granted Oct 15, 2002·28 cites·9 claims
- 3165US2008249025A1Methods and Means For Inhibition of CDK4 ActivityCYCLACEL LTD·Filed 2008·Application pending·0 cites
- 3260US6569833B1Cyclin dependent kinase binding peptidesCYCLACEL LTD·Filed 1996·Granted May 27, 2003·18 cites·22 claims
- 3360US2003203407A1Compositions and methods for monitoring the phosphorylation of natural binding partnersCYCLACEL LTD·Filed 2003·Application pending·0 cites
- 3458US2009270427A1Purine derivativesCYCLACEL LTD·Filed 2009·Application pending·0 cites
- 3555US7223795B2Modified peptide derivatives and methods of use thereofCYCLACEL LTD·Filed 2003·Granted May 29, 2007·2 cites·19 claims
- 3655US2003104504A1Chemical modificationCYCLACEL LTD·Filed 2002·Application pending·0 cites
- 3752US6962792B1Methods and means for inhibition of Cdk4 activityCYCLACEL LTD·Filed 1997·Granted Nov 8, 2005·11 cites·26 claims
- 3852US2007185134A1Inhibitors of cyclin dependent kinases as anti-cancer agentCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 3952US2006148017A1Compositions and methods for monitoring enzyme activityCYCLACEL LTD·Filed 2005·Application pending·0 cites
- 4051US7166475B2Compositions and methods for monitoring the modification state of a pair of polypeptidesCYCLACEL LTD·Filed 1999·Granted Jan 23, 2007·16 cites·4 claims
- 4151US6242201B1Identification of the P21WaF1-PCNA interaction site and therapeutic applications thereofCYCLACEL LTD·Filed 1995·Granted Jun 5, 2001·14 cites·16 claims
- 4251US2019314396A1Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemiaCYCLACEL LTD·Filed 2019·Application pending·0 cites
- 4349US9872874B2Dosage regimen for sapacitabine and seliciclibCYCLACEL LTD·Filed 2013·Granted Jan 23, 2018·0 cites·11 claims
- 4449US2005222054A1Combination comprising a CDK inhibitor and doxorubicinCYCLACEL LTD·Filed 2004·Application pending·0 cites
- 4549US2019298718A1Dosing regimenCYCLACEL LTD·Filed 2018·Application pending·0 cites
- 4649US2005164976A1Combination of a cdk inhibitor and 5-fu for the tratment of cancerCYCLACEL LTD·Filed 2003·Application pending·0 cites
- 4749US2007269433A1Cell cycle progressional proteinsCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 4847US10927113B2Process for preparing purine derivativesCYCLACEL LTD·Filed 2018·Granted Feb 23, 2021·0 cites·14 claims
- 4947US6613878B1PCNA binding substanceCYCLACEL LTD·Filed 1996·Granted Sep 2, 2003·7 cites·18 claims
- 5047US2013005747A1Method for selecting a cancer therapyCYCLACEL LTD·Filed 2011·Application pending·0 cites
Showing the top 50 of 84 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CYCLACEL LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →